Affiliation:
1. First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2. Department of Gastroenterology, 424 General Military Hospital, 56429 Thessaloniki, Greece
3. First Department of Internal Medicine, 424 General Military Hospital, 56429 Thessaloniki, Greece
Abstract
Nonalcoholic fatty liver disease (NAFLD) is emerging as an important risk factor for hepatocellular carcinoma (HCC), whose prevalence is rising. Although the mechanisms of progression from NAFLD to HCC are not fully elucidated, tumor necrosis factor-α (TNF-α) and adiponectin, as well as their interplay, which seems to be antagonistic, may contribute to the pathophysiology of NAFLD-associated HCC. TNF-α initially aims to protect against hepatocarcinogenesis, but during the progression of NAFLD, TNF-α is increased, thus probably inducing hepatocarcinogenesis in the long-term, when NAFLD is not resolved. On the other hand, adiponectin, which is expected to exert anti-tumorigenic effects, is decreased during the progression of the disease, a trend that may favor hepatocarcinogenesis, but is paradoxically increased at end stage disease, i.e., cirrhosis and HCC. These observations render TNF-α and adiponectin as potentially diagnostic biomarkers and appealing therapeutic targets in the setting of NAFLD-associated HCC, possibly in combination with systematic therapy. In this regard, combination strategy, including immune checkpoint inhibitors (ICIs) with anti-TNF biologics and/or adiponectin analogs or medications that increase endogenous adiponectin, may warrant investigation against NAFLD-associated HCC. This review aims to summarize evidence on the association between TNF-α and adiponectin with NAFLD-associated HCC, based on experimental and clinical studies, and to discuss relevant potential therapeutic considerations.
Reference129 articles.
1. Review Article: The Epidemiologic Burden of Non-Alcoholic Fatty Liver Disease across the World;Henry;Aliment. Pharmacol. Ther.,2022
2. Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention;Huang;Nat. Rev. Gastroenterol. Hepatol.,2021
3. Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018
4. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease;Makri;Arch. Med. Res.,2021
5. Cancer Statistics, 2022;Siegel;CA Cancer J. Clin.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献